THE AMENDMENTS

In the Claims:

- 1-17. (Canceled)
- 18. (Currently Amended) The method of Claim 21, wherein the amount of the compound of Formula II, administered to the mammal is sufficient to achieve a concentration on the cervical and/or vaginal mucosa of from about 10⁻⁷ moles/liter to about 10⁻¹ moles/liter.
- 19. (Currently Amended) The method of Claim 21, wherein the amount of the compound of Formula II, administered to the mammal is sufficient to achieve a daily dose of between 1 to 1000 milligrams.
- 20. (Previously Presented) A method of stimulating cervical and vaginal secretions in a mammal in need thereof by administering an effective secretion stimulating amount of a compound of P¹, P⁴-di(uridine 5¹-) tetraphosphate to a mammal in need thereof.
- 21. (Previously Presented) A method of treating a mammal with vaginal dryness by administering an effective vaginal treatment amount of a compound of P¹, P⁴-di(uridine 5*-) tetraphosphate to a mammal in need thereof.
- 22. (Previously Presented) The method according to Claim 21, wherein said compound is topically administered to the cervical or vaginal mucosa of the mammal in a form of a solution, gel, suspension, cream, foam, ointment, pessary, or tablet.
- (Previously Presented) The method according to Claim 21, wherein said compound is systemically administered to the mammal.